These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 18674944)

  • 1. Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy.
    Wendling D; Cedoz JP; Racadot E
    Joint Bone Spine; 2008 Oct; 75(5):559-62. PubMed ID: 18674944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients.
    Wendling D; Cedoz JP; Racadot E
    Clin Rheumatol; 2009 Feb; 28(2):187-90. PubMed ID: 18827961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serum metalloproteinase-3 levels in assessing efficacy of Etanercept in patients with ankylosing spondylitis].
    Wang QH; Zhang SZ; Xue J; Wu HX
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Jul; 39(4):409-14. PubMed ID: 20731042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal anti-TNF antibodies can elevate hemoglobin level in patients with ankylosing spondylitis.
    Bes C; Yazici A; Soy M
    Rheumatol Int; 2013 Jun; 33(6):1415-8. PubMed ID: 23143665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNFα antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.
    Couderc M; Payet S; Henquell C; Dubost JJ; Soubrier M
    Joint Bone Spine; 2010 Oct; 77(5):414-7. PubMed ID: 20542718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
    Woo JH; Lee HJ; Sung IH; Kim TH
    J Rheumatol; 2007 Aug; 34(8):1753-9. PubMed ID: 17610317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study of etanercept for treating ankylosing spondylitis].
    Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
    J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J
    Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
    Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis.
    Maksymowych WP; Rahman P; Shojania K; Olszynski WP; Thomson GT; Ballal S; Wong RL; Inman RD;
    J Rheumatol; 2008 Oct; 35(10):2030-7. PubMed ID: 18785308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparate effects of anti-TNF-α therapies on measures of disease activity and mediators of endothelial damage in ankylosing spondylitis.
    Korkosz M; Gąsowski J; Surdacki A; Leszczyński P; Pawlak-Buś K; Jeka S; Siedlar M; Grodzicki T
    Pharmacol Rep; 2013; 65(4):891-7. PubMed ID: 24145083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
    Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
    Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis.
    Arends S; van der Veer E; Groen H; Houtman PM; Jansen TL; Leijsma MK; Bijzet J; Limburg PC; Kallenberg CG; Spoorenberg A; Brouwer E
    J Rheumatol; 2011 Aug; 38(8):1644-50. PubMed ID: 21632677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reproducibility of the Bath Ankylosing Spondylitis Indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients.
    Madsen OR; Rytter A; Hansen LB; Suetta C; Egsmose C
    Clin Rheumatol; 2010 Aug; 29(8):849-54. PubMed ID: 20306214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of matrix metalloproteinase-3 (MMP-3) and magnetic resonance imaging of sacroiliitis in assessing disease activity in ankylosing spondylitis.
    Soliman E; Labib W; el-Tantawi G; Hamimy A; Alhadidy A; Aldawoudy A
    Rheumatol Int; 2012 Jun; 32(6):1711-20. PubMed ID: 21431945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy.
    Kwon SR; Lim MJ; Suh CH; Park SG; Hong YS; Yoon BY; Kim HA; Choi HJ; Park W
    Rheumatol Int; 2012 Aug; 32(8):2523-7. PubMed ID: 21833531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Stable high interleukin-17A concentration in patients with ankylosing spondylitis treated with tumor necrosis factor-α inhibitors during a year].
    Gaydukova IZ; Rebrov AP; Aparkina AV; Khondkaryan EV
    Ter Arkh; 2017; 89(4):80-85. PubMed ID: 28514405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.